Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (2083)	7/20/1998 12:36:00 PM
From: tom jones	Read Replies (2) \| Respond to of 4676

To all: Comments on fda meeting. You would think the fda would look at this Isis drug like is does all other drugs. But this is the fda and ISIS 2922 would be the first antisense drug to be approved. The fda doesn't want to be known for approving a drug that doesn't work. The people at the fda think their work is much more important then just approving drugs. They must think of what is going to happen to ISIP and other drug companies if antisense is approved not just the simple mater if ISIS 2922 is safe and works as well the other drugs used now for retinitis. I think this is the reason why Isis has been quiet about why they think their drug should be approved. Comments? Tom